Martingale Asset Management L P Grows Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Martingale Asset Management L P increased its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 2.5% during the fourth quarter, Holdings Channel.com reports. The fund owned 15,993 shares of the biotechnology company’s stock after buying an additional 390 shares during the period. Martingale Asset Management L P’s holdings in Blueprint Medicines were worth $1,395,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Blueprint Medicines by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 6,774,884 shares of the biotechnology company’s stock worth $590,905,000 after purchasing an additional 91,450 shares in the last quarter. Wellington Management Group LLP raised its stake in Blueprint Medicines by 8.0% during the fourth quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company’s stock worth $373,421,000 after purchasing an additional 316,754 shares during the period. William Blair Investment Management LLC lifted its holdings in Blueprint Medicines by 16.1% in the fourth quarter. William Blair Investment Management LLC now owns 1,944,695 shares of the biotechnology company’s stock valued at $169,616,000 after acquiring an additional 269,896 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Blueprint Medicines by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 1,490,101 shares of the biotechnology company’s stock valued at $129,996,000 after purchasing an additional 9,914 shares during the last quarter. Finally, Pictet Asset Management Holding SA boosted its stake in Blueprint Medicines by 1.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,183,682 shares of the biotechnology company’s stock worth $103,241,000 after buying an additional 17,175 shares during the period.

Insider Transactions at Blueprint Medicines

In other news, Director Jeffrey W. Albers sold 15,161 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $109.53, for a total transaction of $1,660,584.33. Following the transaction, the director now directly owns 152,396 shares in the company, valued at $16,691,933.88. This represents a 9.05 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Kate Haviland sold 1,446 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the transaction, the chief executive officer now directly owns 149,378 shares in the company, valued at approximately $16,467,430.72. This represents a 0.96 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 31,608 shares of company stock valued at $3,319,587 in the last ninety days. Corporate insiders own 4.21% of the company’s stock.

Blueprint Medicines Stock Performance

Shares of BPMC opened at $80.84 on Friday. Blueprint Medicines Co. has a 52-week low of $73.04 and a 52-week high of $121.90. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The company has a market capitalization of $5.17 billion, a PE ratio of -74.85 and a beta of 0.75. The company has a 50-day simple moving average of $90.91 and a 200-day simple moving average of $93.51.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Equities research analysts predict that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on BPMC shares. Wolfe Research assumed coverage on Blueprint Medicines in a research report on Tuesday, March 18th. They set an “outperform” rating for the company. Morgan Stanley initiated coverage on shares of Blueprint Medicines in a report on Thursday, March 20th. They set an “equal weight” rating and a $100.00 price target for the company. StockNews.com downgraded Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Monday, March 3rd. Stephens reaffirmed an “overweight” rating and issued a $140.00 target price on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Finally, Wedbush reaffirmed an “outperform” rating and set a $128.00 price target on shares of Blueprint Medicines in a research report on Friday, February 28th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $124.95.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.